VU0152100
(Synonyms: 3-氨基-N-[(4-甲氧基苯基)甲基]-4,6-二甲基噻吩并[2,3-B]吡啶-2-甲酰胺,VU152100) 目录号 : GC16819
A muscarinic M4 receptor positive allosteric modulator
Cas No.:409351-28-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
VU0152100 is a selective and positive allosteric modulators of M4 receptor with the EC50 value of 380±93nM[1].
VU0152100 has shown a potent positive allosteric modulators that increase the response of the M4 receptor to the endogenous agonist ACh in in vitro study. In addition, VU0152100 has been reported to dese-dependently potentiate the response to the agonist (ACh) with the EC50 value of 1.9±0.2μM, and increase the maximal response to ACh to approximately 130%. Furthermore, VU0152100 has been revealed to enhance receptor activation by increasing the affinity of M4 for acetylcholine. Apart from these, VU0152100 has been found to induce a 20 to 25-fold leftward shift in the potency of ACh to displace [3H]NMS binding to M4 receptor with the Ki value from 252±19.7nM to 12.2±0.49nM [1].
References:
[1] Brady AE1, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey JK, Conn PJ, Lindsley CW. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther. 2008 Dec;327(3):941-53.
| Cas No. | 409351-28-6 | SDF | |
| 别名 | 3-氨基-N-[(4-甲氧基苯基)甲基]-4,6-二甲基噻吩并[2,3-B]吡啶-2-甲酰胺,VU152100 | ||
| 化学名 | 3-amino-N-[(4-methoxyphenyl)methyl]-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide | ||
| Canonical SMILES | CC1=CC(=NC2=C1C(=C(S2)C(=O)NCC3=CC=C(C=C3)OC)N)C | ||
| 分子式 | C18H19N3O2S | 分子量 | 341.43 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:6): 0.14 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9289 mL | 14.6443 mL | 29.2886 mL |
| 5 mM | 0.5858 mL | 2.9289 mL | 5.8577 mL |
| 10 mM | 0.2929 mL | 1.4644 mL | 2.9289 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet